Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis modelBRAVE, Sandra R; EBERLEIN, Cath; SHIBUYA, Masabumi et al.Angiogenesis (London). 2010, Vol 13, Num 4, pp 337-347, issn 0969-6970, 11 p.Article

Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologiesFARREN, Matthew; WESTON, Susie; WEDGE, Stephen R et al.Angiogenesis (London). 2012, Vol 15, Num 4, pp 555-568, issn 0969-6970, 14 p.Article

Structure―activity relationship of a series of non peptidic RGD integrin antagonists targeting α₅β₁: Part 2DELOUVRIE, Benedicte; AL-KADHIMI, Katherine; JUDE, David A et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 12, pp 4117-4121, issn 0960-894X, 5 p.Article

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancerBRAVE, Sandra R; ODEDRA, Rajesh; WAINWRIGHT, Anna et al.International journal of oncology. 2011, Vol 39, Num 1, pp 271-278, issn 1019-6439, 8 p.Article

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in OncologyPRABHAKAR, Uma; MAEDA, Hiroshi; JAIN, Rakesh K et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 8, pp 2412-2417, issn 0008-5472, 6 p.Article

Structure―activity relationship of a series of non peptidic RGD integrin antagonists targeting α₅β₁: Part 1DELOUVRIE, Bénédicte; AL-KADHIMI, Katherine; JUDE, David A et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 12, pp 4111-4116, issn 0960-894X, 6 p.Article

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted TherapySMITH, Neil R; BAKER, Dawn; WEDGE, Stephen R et al.Clinical cancer research (Print). 2013, Vol 19, Num 24, pp 6943-6956, issn 1078-0432, 14 p.Article

Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growthTAZZYMAN, Simon; BARRY, Simon T; ASHTON, Susan et al.International journal of cancer (Print). 2011, Vol 129, Num 4, pp 847-858, issn 0020-7136, 12 p.Article

AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerWEDGE, Stephen R; KENDREW, Jane; CHESTER, Rosemary et al.Cancer research (Baltimore). 2005, Vol 65, Num 10, pp 4389-4400, issn 0008-5472, 12 p.Article

Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugsREIGAN, Philip; EDWARDS, Philip N; JAFFAR, Mohammed et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 2, pp 392-402, issn 0022-2623, 11 p.Article